Pharmaceutical News

RSS

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Impax Laboratories, Inc. today announced that it has reached agreement with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle pending U.S. litigation with regard to the production and sale of generic formulations of OPANA ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Emerson Ecologics announces exclusive distribution of EcoNugenics' BreastDefend dietary supplement

Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.

9 Jun 2010

Drugs in R&D journal transformed from fee-based access to OA

The Adis journal Drugs in R&D has been transformed from fee-based access to open access, according to its parent company Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Ontario's Community Pharmacies Coalition are extremely disappointed by yesterday's announcement by Health Minister Deb Matthews and the posting of amendments to regulations under the OBDA and DIDFA as it all but assures that Ontario patients will be less able to freely access the front-line community healthcare they have come to rely on.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

UNITAID concerned about infant HIV medication shortage, drug company says supply is sufficient

Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet, UNITAID writes that "[c]losing this factory means that 4,000 to 7,000 babies currently enrolled in treatment plans in developing countries through UNITAID could be left without the medicines they need."

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

8 Jun 2010

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

Elotuzumab shows promise in treating multiple myeloma: Study

A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer. A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism.

8 Jun 2010

Cegedim Dendrite reports 2010 survey results of bio-pharmaceutical industry's market access

Cegedim Dendrite, the leading provider of CRM software and healthcare data to the bio-pharmaceutical industry, today announces the results of The Cegedim Dendrite Market Access Industry Report 2010; a market research survey conducted in May this year across nearly 200 European executives from marketing, market access, market research and sales departments within bio-pharmaceutical organisations.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Pharmaceutical News

Impax reaches agreement with Endo and Penwest to settle pending litigation for OPANA ER

Multiple presentations on nab-driven chemotherapy at 46th ASCO

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Emerson Ecologics announces exclusive distribution of EcoNugenics' BreastDefend dietary supplement

Drugs in R&D journal transformed from fee-based access to OA

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Blood vessel-blocking drug slows prostate cancer progression: Experts

Ontario's Community Pharmacies Coalition reacts to new regulations and vows to fight for patient care

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

UNITAID concerned about infant HIV medication shortage, drug company says supply is sufficient

Endo, Penwest announce settlement of OPANA ER litigation with Impax

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Elotuzumab shows promise in treating multiple myeloma: Study

Cegedim Dendrite reports 2010 survey results of bio-pharmaceutical industry's market access

Research findings open door to development of new therapies for lymphomas, leukemias

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News